Global Opioid-Induced Constipation Market Report 2018-2022 with Market Position of Key Vendors - AstraZeneca, Bausch Health, Takeda Pharmaceutical & Merck - ResearchAndMarkets.com |
Wednesday, 09 January 2019 23:06 |
Jan. 10, 2019 09:15 UTC Global Opioid-Induced Constipation Market Report 2018-2022 with Market Position of Key Vendors - AstraZeneca, Bausch Health, Takeda Pharmaceutical & Merck - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)-- The "Global Opioid-Induced Constipation Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The opioid-induced constipation market will register a CAGR of more than 32% by 2022. Rise in incidence of chronic diseases such as arthritis, back pain, and migraine is likely to drive growth in the market. The incidence of chronic pain is increasing across the world, owing to the several reasons, including lifestyle changes, rise in number of injuries, growth in number of surgeries, and painful medical conditions. Market Overview Rise in OIC cases among elderly Rise in incidences of diseases associated with old age, impaired body functions, and increase in the use of medicines such as antidepressants and anticholinergics have collectively led to high prevalence of constipation among the elderly population. This drives growth in the opioid-induced constipation market. Use of conventional laxatives for OIC The use of laxatives for OIC is a major challenge that is reducing sales of approved drugs meant for the treatment of OIC. Competitive Landscape The market appears to be fragmented and with the presence of several companies including Takeda Pharmaceutical and Merck, the competitive environment is quite intense. Factors such as the rise in incidence of chronic diseases such as arthritis, back pain, and migraine and the rise in OIC cases among elderly, will provide considerable growth opportunities to opioid-induced constipation manufactures. AstraZeneca, Bausch Health, Takeda Pharmaceutical, and Merck are some of the major companies covered in this report. Key Topics Covered: PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE
PART 05: PIPELINE ANALYSIS PART 06: MARKET SIZING
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
PART 09: MARKET SEGMENTATION BY CLASS OF DRUGS
PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE
PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
PART 16: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/research/vhhgw9/global?w=4 View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005236/en/ Contacts ResearchAndMarkets.com Source: Research and Markets "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |